Cavadis is a Dutch biomedical company active in the field of cardiovascular risk assessment. Our mission is to identify patients at risk of developing heart attacks and strokes. The ultimate goal is to develop meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
Recently our company identified several novel biomarkers predictive for cardiovascular events. Cavadis' biomarkers form the basis for developing prognostic assays that enable individual cardiovascular risk assessment. Our proprietary biomarkers outperform traditional risk factors and show an impressive shifting power in patients classified as high or low risk according to classical risk factors. Improved risk stratification impacts clinical decision making as high-risk patient groups are likely to receive more aggressive treat-to-target medication schemes or may become eligible for novel biopharmaceuticals currently under development for cardiovascular indications.
Our goal is to develop clinically meaningful risk stratification tools that will help to personalize treatment and achieve better patient outcomes.
- Cavadis identified novel biomarkers predictive for cardiovascular events.
- Cavadis' biomarkers form the basis for developing prognostic tests that allow individual risk assessment.
- Cavadis' develops clinically meaningful risk stratification tools to personalize treatment and achieve better patient outcomes.
Related items
NewsGet the latest insights in Cavadis' business and research.
read more